-
Sandoz Expands Antibiotics Production with New Austrian Factory
•
Sandoz (OTCMKTS: SDZNY), a Swiss pharmaceutical company, has announced the opening of a new antibiotics manufacturing site in Austria, marking a significant expansion in its production capabilities. The annual production capacity in the city has increased from 200 million to 240 million packages, following the completion of a 3,000 square…
-
Shanghai Institute’s Biosimilar Rituximab Approved by NMPA for Lymphoma Treatments
•
Shanghai Institute of Biological Products Co., Ltd has announced that its biosimilar version of Roche/Genentech’s Mabthera (rituximab) has received approval from the National Medical Products Administration (NMPA) for the treatment of Non-Hodgkin’s lymphoma, including follicular non-Hodgkin’s lymphoma and CD20 positive diffuse large B-cell non-Hodgkin’s lymphoma, as well as chronic lymphoblastic…
-
EMA Panel Backs Novartis’s Fabhalta for PNH Treatment, Awaits EC Decision
•
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Novartis’s (NYSE: NVS) Factor B inhibitor Fabhalta (iptacopan) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults with hemolytic anemia. The European Commission (EC) is anticipated to make a…
-
Sumitomo Pharma’s China CEO Highlights Strategic Importance of Local Market
•
Yoshitaka Koketsu, CEO of Sumitomo Pharma (TYO: 4506) (China) Co., Ltd, the Chinese subsidiary of Japan-based Sumitomo Pharma, has expressed strong optimism about the company’s prospects in the local market in an interview with Shanghai Daily. Koketsu emphasized that China, as the world’s second-largest pharmaceutical market, holds strategic significance for…
-
Roche Invests EUR 90 Million in New Gene Therapy Center in Germany
•
Swiss pharmaceutical giant Roche (SWX: RO) has inaugurated a new gene therapy development center in Germany, following an investment of EUR 90 million (USD 97.4 million). The expansive 2,500 square meter facility is designed to specialize in the production of gene vectors for clinical trials across various therapeutic areas, including…
-
Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first quarter of 2024. Despite expectations that its top-selling interleukin blocker Dupixent (dupilumab) will face challenges from a co-pay assistance program in the first quarter, the company projects that the drug’s sales will reach EUR 13…
-
FibroGen’s Roxadustat Approved in Macau for Chronic Kidney Disease-Related Anemia
•
FibroGen Inc. (NASDAQ: FGEN), a biopharmaceutical company based in the US, has announced that it has received marketing approval in Macau for its drug roxadustat. The drug is indicated for the treatment of anemia caused by chronic kidney disease (CKD), encompassing both dialysis and non-dialysis patients. Roxadustat, an oral hypoxia-inducible…
-
China’s Commerce Minister Meets with Global Pharma Leaders to Discuss Innovation Cooperation
•
China’s Minister of Commerce, Wang Wentao, convened a high-level meeting with top executives from the global pharmaceutical industry, including leaders from Bristol-Myers Squibb, GlaxoSmithKline, Danaher, Pfizer, Abbott, Sanofi, Takeda Pharmaceuticals, Gilead, Merck, Sharp & Dohme, and more. Also in attendance was a representative from the Pharmaceutical Research and Manufacturers of…
